May 5, 2025 | Press Release
Vienna, Austria – May 5, 2025 Breakthrough in Hypoxic Modification for Head and Neck Cancer Patients receiving Chemoradiation Treatment Presented at ESTRO 2025. Clinical Study Demonstrates Improved Locoregional Control with Nimorazole in Advanced Head and Neck Cancer....
Apr 23, 2025 | Press Release
Hørsholm, Denmark – April 23, 2025 Lunatus and AFYX Therapeutics A/S are pleased to announce a new distribution and sales collaboration for AFYX’s induction of labor product, Gefena (Misoprostol 25μg tablet). Under this agreement, Lunatus will distribute,...
Feb 13, 2025 | Press Release
In Q4 2024, AFYX Group reported total revenue of DKK 12.9 million, up from DKK 8.9 million in Q4 2023. The increase was driven primarily by higher sales of Diaphine, along with growth in Nimorazole sales, largely attributed to our customers in Norway—a trend we expect...
Feb 5, 2025 | Press Release
AFYX Therapeutics is a growing and we have two exciting job opportunities inside Finance & Accounting and Office & Warehouse Administration, respectively. See job posts directly on LInkedIn: Financial Accountant, Copenhagen Area (Hørsholm) – Application...
Jan 13, 2025 | Press Release
Hørsholm, Denmark – January 13, 2025 AFYX Therapeutics A/S and Cevidra SAS are pleased to announce a strategic partnership aimed at bringing innovative treatments for Head and Neck Cancer to the French market. Under this collaboration, Cevidra will serve as the local...
Jan 6, 2025 | Press Release
Hørsholm, Denmark – January 6, 2025 Er-Kim and AFYX Therapeutics A/S announced today a distribution and sales collaboration for two AFYX products. The two companies have entered a mutual sales and distribution collaboration where Er-Kim will sell and distribute the...
